FRTX 02
Alternative Names: BBI-02; FRTX-02; VRN 02Latest Information Update: 28 Feb 2024
Price :
$50 *
At a glance
- Originator Voronoi
- Developer Fresh Tracks Therapeutics; Voronoi
- Class Anti-inflammatories; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Inflammatory bowel diseases; Psoriasis; Systemic lupus erythematosus
- Discontinued Autoimmune disorders; Rheumatoid arthritis; Type 1 diabetes mellitus
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Atopic-dermatitis in South Korea (PO)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in South Korea (PO)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Psoriasis in South Korea (PO)